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Abstract. 
 
Survivin is a cancer-associated protein that is pivotal for cellular life and death: it is an 
essential mitotic protein and an inhibitor of apoptosis. In cancer cells, a small pool of 
survivin localises to the mitochondria, the function of which remains to be elucidated. 
Here, we report that mitochondrial survivin inhibits the selective form of autophagy, 
called “mitophagy”, causing an accumulation of respiratory defective mitochondria. 
Mechanistically the data reveal that survivin prevents recruitment of the E3-ubiquitin 
ligase Parkin to mitochondria and their subsequent recognition by the 
autophagosome. The data also demonstrate that, as a consequence of this blockade, 
cells expressing high levels of survivin have an increased dependency on anaerobic 
glycolysis. As these effects were found exclusively in cancer cells they suggest that the 
primary act of mitochondrial survivin is to force cells to implement the “Warburg 
Effect” by inhibiting mitochondrial turnover.  
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Introduction. 
Survivin is a protein at the interface of cellular life and death, as it guides mitosis and 
inhibits apoptosis (Wheatley and Altieri, 2019). It is over-expressed in cancer and is 
associated with poor patient prognosis (Ambrosini et al. 1997; Escuín & Rosell 1999, 
reviewed in Jaiswal et al. 2015). Its abundance correlates directly to chemotherapy 
resistance highlighting it as a potential anti-cancer target (Morrison et al., 2012). 
Survivin localises in several distinct pools (Fortugno et al., 2002). During mitosis and 
as part of the chromosomal passenger complex, it directs chromosome congression 
and segregation, as well as cytokinesis. When present in interphase, its predominantly 
cytosolic localisation is key to its anti-apoptotic function. The focus of this paper is the 
mitochondrial pool of survivin, which is found only in cancer cells (Dohi et al., 2004). 
What survivin does when resident in the mitochondria is a matter of ongoing debate 
(Hagenbuchner et al., 2013; Rivadeneira et al., 2015), although early evidence 
suggested that it may be a store of survivin with greater anti-apoptotic potential than 
the cytosolic pool “primed” in readiness to respond to pro-apoptotic signals (Dohi, Xia 
and Altieri, 2007). 
Malignant transformation requires cellular changes that enable unrestricted 
proliferation and circumvention of programmes of cell death, such as apoptosis and 
autophagy. For decades the mitochondrion has been seen as a by-stander of 
malignant transformation, gaining inactivating mutations from various sources that 
switch cellular metabolism from oxidative phosphorylation (OXPHOS) to glycolysis 
(Warburg, 1956). More recently it has begun to be appreciated that mitochondria 
actively participate in driving tumour progression and malignant transformation 
(Chatterjee, Dasgupta and Sidransky, 2011; Yadav and Chandra, 2013; van Gisbergen 
et al., 2015) 
Mitochondrial homeostasis, including their quality and length is maintained by the 
dynamic processes of fusion and fission, which are controlled by factors within the 
mitochondria and in the cytosol (Westermann, 2010a; East and Campanella, 2016). In 
healthy cells, the balance between fusion and fission is tightly controlled to allow for 
the timely removal of non-functional mitochondria without affecting respiration 
(Nunnari et al., 1997). In cancerous cells, this process is commonly deregulated 
resulting in the gradual accumulation of mitochondrial DNA (mtDNA) mutations that 
eventually trigger the loss of the respiratory apparatus (Balaban, Nemoto and Finkel, 
2005; Porporato et al., 2017), causing a reduction in OXPHOS, and greater dependency 
on glycolysis, hence evoking the “Warburg Effect” (Merz and Westermann, 2009). In 
normal proliferating cells, fusion is important for the maintenance of healthy 
mitochondria as it can rescue damaged mitochondria by mixing their contents with 
healthy mitochondria (Westermann, 2010b). Opposing fusion is fission, a process that 
generates mitochondrial fragments. In mitosis fission occurs to ensure that the 
organelle is correctly inherited (Twig, Hyde and Shirihai, 2008), but it is also necessary 
to maintain mitochondrial homeostasis as it precedes the removal of defective 
mitochondria by the selective form of autophagy, called “mitophagy” (Twig and 
Shirihai, 2011; Redmann et al., 2014). Together, with mitochondrial biogenesis, 
mitophagy is a quality control mechanism that determines mitochondrial mass 
(Jornayvaz and Shulman, 2010). 
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Autophagy delivers defective organelles to autophagosomes, which fuse with 
lysosomes to degrade and recycle their constituents (Youle and Narendra, 2011). 
Organelles destined for recycling can be delivered to the autophagosome by two 
distinct pathways, either ubiquitin-dependent or ubiquitin-independent (Zaffagnini 
and Martens, 2016). The ubiquitin-dependent pathway requires ubiquitination of 
defunct organelles by E3-ubiquitin ligases and their subsequent recognition by 
ubiquitin binding proteins, which enables extension of the pre-autophagosomal 
(phagophore) membrane and their complete engulfment into the autophagosome 
(Shaid et al., 2013). Mitochondrial recycling relies upon the action of PTEN-induced 
kinase 1 (PINK) and the E3-ubiquitin ligase Parkin (East and Campanella, 2016). 
Alterations to either of these processes result in the accumulation of defunct, 
metabolically inactive mitochondria. Reactive oxygen species (ROS), which are a 
principle cause of mitochondrial DNA (mtDNA) damage, are a by-product of OXPHOS. 
If mitochondria harbouring mtDNA lesions are not removed in a timely manner they 
can promote tumourigenesis (Ott et al., 2007). Cancer cells typically circumvent the 
damage by using glycolysis to generate ATP. Even though it is a less efficient means of 
ATP production, one of its major advantages is that it does not produce ROS and thus 
does not cause mtDNA mutations. Mitochondrial quality control is a relatively 
unexplored aspect of cancer, but given the accumulating evidence that alterations in 
mitophagy can bestow chemotherapy resistance (van Gisbergen et al., 2015), 
understanding its contribution to the diseased state may reveal an Achilles’ heel of 
cancer (Hagenbuchner et al., 2016) 
Here we test the hypothesis that survivin regulates mitochondrial homeostasis and 
respiratory dependence in cancer cells. We report that in cancer cells, survivin 
increases mitochondrial mass and reduces mtDNA quality by inhibiting mitophagy. We 
propose that due to this accumulated load of respiratory inactive mitochondria, 
cancer cells with high expression of survivin undertake the Warburg transition and 
become reliant on glycolysis for survival.  
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Results. 
Survivin is found in the mitochondria of transformed cells. 
 
It has previously been reported that a sub-population of survivin localises to the 
mitochondria in cancer cells. To verify that this was the case in the cells being 
examined here, we carried out subcellular fractionation to enrich for mitochondria in 
two cancerous lines: HeLa (cervical cancer) and U2OS (osteosarcoma), and in normal 
fibroblasts (MRC5), see Figure 1A. All lines were engineered to ectopically express 
survivin, C-terminally tagged with GFP or GFP alone (control). As indicated by 
enrichment of VDAC, and minimal contamination of tubulin (cytosolic marker) and 
histone H3 (nuclear marker), while GFP (control) was excluded from mitochondria in 
all lines, survivin-GFP was present in the mitochondria of HeLa and U2OS, but not 
MRC5 cells. These data corroborate previous work (Dohi et al., 2004), and further 
demonstrate that this is also the case when survivin is present at high levels through 
ectopic expression.  
Manipulating survivin expression alters mitochondrial mass and affects expression 
of fusion and fission proteins in cancer cells, but not proteins required for 
mitochondrial biogenesis. 
To determine whether mitochondrial survivin can influence expression of 
mitochondrial proteins, including those responsible for mitochondrial dynamics, we 
analysed whole cell extracts (WCE) of HeLa cells expressing GFP or survivin-GFP by 
immunoblotting (Figure 1B). Blots were probed for the fission proteins DRP1 and FIS1, 
the fusion proteins, MFN1, MFN2 (OMM), and OPA1 (IMM); mitochondrial mass was 
assessed using anti-VDAC. Semi-quantitative analysis of these blots (Figures 1C) was 
calculated by normalising the band intensity of the protein of interest against the anti-
tubulin loading control and presented as fold change of survivin-GFP compared with 
GFP. This analysis showed that VDAC levels increased significantly when survivin was 
expressed. In addition to this, DRP1, MFN-2 and OPA1 expression also increased, while 
the fission receptor protein, FIS1, decreased. Given that total mitomass increased, we 
recalculated the fold change normalised to VDAC. This revealed that only the change 
in FIS1 occurred independently of mitomass (Figure 1D). In contrast to the results in 
HeLa cells, none of these alterations were observed in normal MRC5 fibroblasts 
expressing survivin-GFP (Figure 1E & F).  To determine whether changes in expression 
of these proteins could be attributed to changes at the transcriptional level, 
quantitative PCR (qPCR) was performed on extracts from HeLa cells and fold change 
in expression between survivin-GFP and GFP controls plotted. No change in VDAC 
mRNA was observed but there was a statistically significant increase in DRP1 mRNA 
(encoded by DNML-1), and a decrease in FIS1 mRNA (Figure 1G), which could account 
for the changes observed at the protein level.  
 
To clarify whether the increase in mitomass was caused by elevated mitochondrial 
biogenesis, HeLa and MRC5 WCEs expressing GFP or survivin-GFP were run on an SDS-
page gel and immunoblotted with the biogenesis marker PGC1-α (Figure 1H and J). 
Semi-quantitative analysis showed that protein expression was decreased in HeLa 
cells (Figure 1I) and not altered in MRC5 cells (Figure 1K). Thus, we conclude that the 
observed increase in mitomass is not due to increased mitochondrial biogenesis.  
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted April 21, 2020. . https://doi.org/10.1101/2020.04.21.052662doi: bioRxiv preprint 
6 
 
 
Having established that survivin overexpression increases mitomass and decreases 
FIS1 levels, we next asked whether depleting it would have the opposite effect. To 
investigate this survivin-specific siRNA was performed (48h) on HeLa and MRC5 cells 
(Figure S1). WCEs were separated by SDS-PAGE, transferred to nitrocellulose and 
probed for mitochondrial proteins as described above. Semi-quantitative analysis of 
blots was used to determine the fold change of each protein in siRNA treated versus 
untreated cells and normalised to tubulin. Survivin depletion caused a significant 
reduction in VDAC and MFN1 expression and no change to FIS1 in HeLa cells (Figure 
S1A and C). By contrast none of these effects were observed in MRC5 cells (Figure S1B 
and D). These data complement the overexpression data, and collectively prove that 
changes in survivin expression alter mitochondrial mass in cancerous but not in 
normal cells.  
 
Survivin increases mtDNA copy number but mtDNA integrity is compromised. 
To confirm that survivin expression increases mitochondrial mass, we quantified 
mitochondrial DNA (mtDNA) copy number. Genomic DNA was extracted from HeLa or 
MRC5 cells expressing either GFP or survivin-GFP, or after siRNA depletion.  qPCR was 
used to determine the abundance of the mtDNA encoded tRNA(LEU) gene, which was 
then compared to the stably expressed nuclear reference genes ACTB (actin) and 
TUBB (tubulin). Fold change of RNA between cells expressing survivin-GFP and GFP 
was then calculated and presented on a Log2 scale. Survivin overexpression increased 
mtDNA tRNA(LEU) gene expression in HeLa cells (Figure 2A), and decreased it in MRC5 
cells (Figure 2B). Thus, by an independent method, these data concur that mitomass 
is elevated by survivin expression in cancer cells. 
Next, we examined the quality of the mtDNA using a PCR-based lesion frequency 
assay. Briefly, genomic DNA was prepared from cells as described for Figure 2A and B 
and PCR reactions carried out to produce either a ‘long read’ (9kb) or a ‘short read’ 
(150 bp) product. In this assay if mtDNA is intact both products will be generated, 
however, if the DNA polymerase encounters lesions, it will stall and less 9kb product 
will form. The 150 bp product is used as a loading control. As shown in Figure 2C and 
D, when normalised to the 150 bp band and analysed semi-quantitatively, fewer 9kb 
products were generated in HeLa cells expressing survivin, compared to the GFP 
control, indicating their mtDNA had more lesions. Conversely survivin depletion 
increased the 9kb product suggesting that in these cells the mtDNA was intact (Figures 
2E and F). In contrast, in MRC5 cells survivin expression actually increased the 
production of the 9kb product (Figures 2G and H), whereas its depletion had no effect 
(Figure 2I and J). Taken together these data suggest that survivin increases mtDNA 
copy number but reduces its quality specifically in cancer cells.  
Survivin expression reduces oxidative phosphorylation in cancer cells. 
As mitochondrial quality was impaired, we next asked whether survivin expression 
also affected respiration. To address this a resazurin assay was carried out at 0.5h 
intervals over 4h on mitochondria isolated from HeLa, U2OS or MRC5 cells (Figure 3). 
Both HeLa and U2OS cells expressing survivin-GFP showed a significant decrease in 
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resorufin fluorescence compared to GFP expressing cells (Figure 3A & C). To ensure 
the observed alterations were due to changes in OXPHOS and not the mitochondrial 
TCA cycle, we also determined the response of each line to the complex V inhibitor, 
oligomycin (Figures 3B, D and F). Mitochondria isolated from both HeLa and U2OS cells 
expressing GFP were more sensitive to oligomycin than those from survivin-GFP cells 
(Figure 3B & D), suggesting that survivin significantly reduced OXPHOS in cancer cells. 
In contrast, no difference was seen in the ability of MRC5-derived mitochondria to 
metabolise resazurin (Figure 3E and S2). In addition, MRC5 cells expressing survivin-
GFP tagged with a bona fide mitochondrial targeting sequence from cytochrome c 
oxidase subunit VIIIA, forcing survivin to be mitochondrial, reduced mitochondrial 
metabolism in a manner seen as in HeLa and U2OS cells (Figure 3F). From these data 
we conclude that survivin specifically inhibits reduction reactions when present within 
the mitochondria.  
Survivin expression increases glucose consumption and lactate production.  
As survivin overexpression was found to reduce OXPHOS, we next asked whether 
cancer cells compensated for this reduction by increasing anaerobic respiration. To 
test this, we used luciferase-based assays to measure glucose consumption and 
lactate production. Survivin-GFP HeLa cells had a significantly lower glucose 
concentration (Figure 3G) and higher rate of lactate production (Figure 3H) compared 
to GFP expressing cells 2h post-seeding. Moreover, the rates at which glucose was 
consumed and lactate concentration rose was significantly higher than those 
observed in GFP cells. As both cell lines grew at the same rate (Figure 3I), we conclude 
that the differences observed were due primarily to metabolic adjustments and not 
differences in proliferation. 
Survivin reduces the sensitivity of cancer cells to chloroquine. 
Based on the observations thus far we hypothesised that survivin inhibits the removal 
of defective mitochondria by the selective autophagic process of “mitophagy”.  To test 
this, cells over-expressing GFP or suvivin-GFP were exposed to the autophagy inhibitor 
chloroquine (CQ) for 16 h, the mitochondria isolated and a resazurin assay performed. 
As shown in Figures 4A-D, CQ treatment (50 and 150 µM) reduced metabolism of 
mitochondria isolated from GFP-expressing cancer cells, which is consistent with a 
block on the removal of defunct mitochondria. However, mitochondria from survivin-
GFP cells showed no reduction in metabolism, which even slightly increased in 
response to CQ. Consistent with the lack of survivin in the mitochondria of normal 
cells, those isolated from MRC5 GFP or survivin-GFP cells responded similarly to CQ 
(Figure 4E and F). Taken together these data suggest that metabolically compromised 
mitochondria accumulate when survivin is expressed because it inhibits mitophagy.  
Survivin-depletion causes mitochondrial fragmentation in cancer cells. 
Next, we used a combination of fluorescent mitochondrial stains and live imaging to 
observe the total mitochondrial network in HeLa cells transiently overexpressing 
GFP/RFP or survivin-GFP/survivin-RFP, or depleted of survivin. In HeLa cells 
mitochondrial morphology was unaffected by ectopic expression of survivin (Figures 
5A and B, S3), however, consistent with the immunoblotting and qPCR data, when 
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total pixel intensity was measured it was apparent that mitomass was increased when 
survivin-RFP was expressed (Figure 5C). Conversely, its depletion caused 
mitochondrial fragmentation (Figures 5E and F, S4A). We then monitored the 
mitochondrial membrane potential using TMRE or MitoTracker Far Red; two 
fluorescent molecules that only highlight polarised mitochondria. The average signal 
intensity was quantified and normalised to the average intensity of MitoTracker Green 
to account for mitochondrial mass (TMRE/MTFR:MTG). In HeLa cells, there was a slight 
reduction in OMM potential in the presence of survivin-GFP, but using this particular 
combination of dyes, (which was necessary for imaging purposes) it was not deemed 
significant (Figure 5D). In the converse experiment survivin depletion reduced the 
mitochondrial membrane potential (Figure 5G), and in MRC5 cells no alterations to 
mitochondrial morphology (Figure 5H) or membrane potential were observed after 
survivin ablation (Figure 5I, S4B). Thus, we conclude that specifically in cancer cells, 
loss of endogenous survivin increases mitochondrial fission and can depolarise the 
OMM.  
Survivin does not inhibit mitophagic steps preceding mitochondrial translocation of 
Parkin.  
As experiments described thus far suggested that survivin inhibits mitophagy, our final 
aim was to determine where survivin was operating in the mitophagic pathway. To 
address this HeLa cells expressing GFP/survivin-GFP or RFP/survivin-RFP were treated 
with FCCP (10 μM, 6h) to depolarise the mitochondria and stimulate mitophagy. They 
were then stained with MitoTracker Red to visualise the mitochondrial network, and 
MitoTracker Green/MitoTracker Far Red to determine membrane polarisation 
respectively. As shown in Figure 6A and B, FCCP caused mitochondrial fission similarly 
in both cell lines, demonstrating that survivin cannot stop chemically triggered 
mitochondrial fragmentation. Under these conditions, survivin expression did not 
prevent OMM depolarisation (Figure 6C). 
Next, to determine whether survivin alters PINK1 stabilisation, HeLa, U2OS or MRC5 
cells were treated with FCCP (10 μM) and Chloroquine (CQ; 100 μM) for 6, 12 or 24 h, 
WCE prepared and immunoblots probed for PINK1 to determine its stability post 
mitophagy stimulation (Figure 6D, F and H). Semi-quantification revealed no 
alterations to PINK1 stabilisation over the time course in either cell line (Figure 6E, G 
and I). Finally, to determine if survivin alters the interaction of PINK1 and its target E3-
ubiquitin ligase Parkin, we performed a pulldown with recombinantly expressed GST-
Parkin in the presence of a HeLa WCE expressing GFP or survivin-GFP (Figure 6J). 
Immunoblotting of the GST-pulldown assay shows survivin does not alter the 
interaction of PINK1 and GST-Parkin.  
Survivin prevents Parkin recruitment to the mitochondria. 
We then asked if survivin altered the recruitment of Parkin to the mitochondria post 
mitophagy stimulation. HeLa and MRC5 cells were transiently transfected with the 
mitophagy-specific E3-ligase, Parkin, N-terminally tagged with mCherry (a gift from 
Prof. S. Martin, Dublin), and the FCCP experiment repeated. Here a marked difference 
was seen: mCherry-Parkin was recruited to the mitochondria of GFP-HeLa cells after 
FCCP treatment, but it was retained in the cytoplasm in survivin-GFP cells (Figure 7A), 
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and trend was confirmed by phenotype counting and quantification (Figure 7B). 
Conversely, the mitochondrial recruitment of mCherry-Parkin was unaffected in MRC5 
cells expressing survivin-GFP (Figure 7C; images shown in Figure S5). From this we 
conclude that in cancer cells, after mitochondrial fragmentation and depolarisation, 
survivin prevents Parkin recruitment from the cytosol to the mitochondria, which 
blocks mitophagy. 
Survivin decreases mitochondrial co-localisation with lysosomes after mitophagy 
stimulation.  
To further confirm how survivin affects mitophagy, HeLa cells expressing RFP or SVN-
RFP were treated with FCCP as previously described, and stained with LysoTracker 
Blue to observe autophagosomes, and MitoTracker Green to observe mitochondria 
(Figure 8A, S6). Co-localisation analysis was then carried out to assess the proportion 
of the mitochondrial network that co-localised with lysosomes. This demonstrated 
that post FCCP treatment, more mitochondria and lysosomes co-localised in RFP-
expressing cells than in SVN-RFP cells, as shown by pixel intensity line plots (Figure 8B 
and C) and whole pixel co-localisation analysis of images (Figure 8D).  
Survivin mimics the effect of Bcl-2 upon mitophagy.  
Finally, to determine whether of survivin collaborates with the apoptosis inhibitor Bcl-
2 during mitophagy, HeLa cells expressing GFP or survivin-GFP were treated with the 
Bcl-2 inhibitor Navitoclax (1μM) and 10 μM FCCP to stimulate mitophagy post 
transfection with mCherry-Parkin. Here, mCherry-Parkin translocation to the 
mitochondrion was increased after FCCP treatment with Navitoclax in cells expressing 
survivin-GFP, but not in GFP expressing cells (Figure S7A) quantified in (Figure S7B). A 
UV dose response curve was simultaneously performed to prove that Navitoclax 
(1μM) was sufficient to inhibit Bcl-2 activity (Figure S7C). From these data we conclude 
the effect of survivin on mitophagy may be increased by collaboration with Bcl-2.  
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Discussion. 
Survivin is an essential protein that is deregulated in cancer, becoming present 
throughout the cell cycle, rather than being confined to G2 and M-phases (Barrett, 
Osborne and Wheatley, 2009). In transformed cells in interphase it is predominantly 
cytoplasmic, shuttling between the cytoplasm and nucleus in a CRM1/exportin-
dependent manner (Colnaghi et al., 2006; Engelsma et al., 2007; Stauber, Mann and 
Knauer, 2007). Cytoplasmic survivin inhibits apoptosis, and it has been suggested that 
prior residence in the mitochondria can enhance this activity (Dohi, Xia and Altieri, 
2007). Consistent with previous studies (Dohi et al., 2004; Dohi, Xia and Altieri, 2007; 
Hagenbuchner et al., 2013, 2016; Rivadeneira et al., 2015), we have found that 
survivin only accesses the mitochondria of transformed cells. Although survivin is 
essential, presumably its mitochondrial residence is not, and constitutes a gain of 
function over its normal roles.  
In this study we tested the hypothesis that survivin interferes with mitochondrial 
homeostasis and alters respiratory dependence in cancer cells. Mitochondria are 
dynamic organelles that regulate cellular metabolism and survival. The opposing 
pathways of mitochondrial biogenesis and autophagic degradation control their 
quantity and quality. Combined with fusion and fission, these mechanisms govern 
mitochondrial activity (Palikaras, Lionaki and Tavernarakis, 2015), and alterations to 
any one of these processes have been linked to ageing and disease (Redmann et al., 
2014). In cancer cells these processes are often deregulated, consequently 
mitochondrial health is compromised: mtDNA harbouring mutations accumulate, 
respiratory efficiency declines, and ultimately cells switch from OXPHOS to glycolytic 
dependence (Merz and Westermann, 2009) (Sumpter et al., 2016). OXPHOS itself 
plays a major role in mtDNA damage as it produces ROS that continuously bombard 
the mtDNA causing lesions (Ray, Huang and Tsuji, 2012)(Sabharwal and Schumacker, 
2014). Healthy cells respond to this damage by removing the affected sections of 
mitochondria using a selective form of autophagy called “mitophagy” (see Figure S8). 
Mitophagy commences with mitochondrial fission, which produces asymmetrical 
daughter mitochondria, one with an increased membrane potential that can fuse with 
healthy mitochondria (Twig et al., 2008), and one with a depolarised membrane that 
is targeted for mitophagy (Elmore et al., 2001; Nicholls, 2004). Depolarisation of the 
OMM of defunct mitochondria stabilises the serine/threonine kinase PINK1, which 
phosphorylates the E3-ligase Parkin at Ser65, and activates it. Parkin then accumulates 
at the OMM (Vives-Bauza et al., 2010; Youle and Narendra, 2011) where it mediates 
ubiquitination of VDAC1 (Kazlauskaite et al., 2014). In turn VDAC-ubiquitination 
stimulates translocation of the autophagic adaptor protein, p62 to the mitochondria, 
which signals their engulfment by pre-autophagosomes via interaction with LC3 (Lee 
et al., 2010; East and Campanella, 2016). 
As indicated by increased expression of VDAC, mtDNA copy number and MitoTracker 
Green pixel area, ectopic expression of survivin caused an increase in total 
mitochondrial mass. We also noted that VDAC was being affected post-translation, 
while FIS1 levels, which decreased when survivin levels were elevated, were affected 
by transcriptional repression. We have also found that survivin does not increase 
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mitochondrial biogenesis, which combined with the aforementioned data, suggests 
survivin specifically increases mitochondrial mass by inhibiting mitophagy. This is 
further confirmed by the reduction in co-localisation of lysosomes and mitochondria 
post mitophagy stimulation. 
In addition to the increase in mitomass, we found that cancerous cells expressing 
survivin had poor quality mtDNA, and that survivin suppressed OXPHOS and increased 
respiratory dependency on glycolysis in these cells. In general, depleting survivin had 
the converse effect to overexpression, and all effects were specific to cancer cells. 
Moreover, using a bona fide mitochondrial-targeting signal from cytochrome c oxidase 
subunit VIIIA we were able to force non-cancerous MRC5 cells to acquire the same 
mitochondrial characteristics as the cancerous cells tested. It is well documented that 
when mitophagy is inhibited, mitochondria with mtDNA lesions accumulate within the 
cell. This can directly impact the activity of mtDNA encoded proteins, notably 
members of the electron transport chain (Sumpter et al., 2016) which directly impacts 
mitochondrial metabolism. Mitophagy can be artificially blocked using general 
autophagy inhibitors, such as CQ, which has been shown to reduce mitochondrial 
metabolism in the described manner (Redmann et al., 2017a). Here, we saw no further 
reduction in the respiration of mitochondria isolated from survivin-GFP expressing 
cancer cells after treatment with CQ (Figure 4), therefore allowing us to conclude that 
survivin modifies mitochondrial metabolism specifically due to alterations to 
mitophagy. Survivin inhibits mitophagy, causing an accumulation of respiratory 
defective organelles which in turn reduces OXPHOS (Redmann et al., 2017b). 
Moreover, as OXPHOS was altered to the same degree by CQ treatment in MRC5 cells 
irrespective of survivin expression, we conclude that this change is due to the 
mitochondrial pool of survivin.  
When determining where survivin acts in the mitophagic pathway, we found that 
neither mitochondrial fission, OMM depolarisation, PINK1 stabilisation nor its 
interaction with the E3 ubiquitin ligase Parkin was affected. Instead survivin prevents 
the recruitment of Parkin to the mitochondria. It has previously been reported that 
survivin inhibits the activities of PINK/Parkin, and that this response causes survivin 
degradation (Hagenbuchner et al., 2016). While our study also links survivin and 
Parkin, we offer a slightly alternative interpretation: rather than causing its own 
demise, survivin inhibits mitophagy by preventing Parkin from translocating to the 
mitochondria, and the resulting accumulation of mitochondria with damaged mtDNA 
ultimately forces the cell to switch from oxidative phosphorylation to glycolysis. As we 
have previously shown that survivin can inhibit autophagic flux (Humphry and 
Wheatley, 2018), we suggest that survivin can interfere with mitophagy both by 
inhibiting Parkin recruitment to the OMM, and later, preventing flux (Figure S8). 
Although a less efficient means of respiration, glycolysis produces less ROS, and thus, 
in addition to the initial survival response, this switch can provide cancer cells with a 
further survival advantage.  
Our findings with survivin mirror these described by (Hollville et al., 2014a), in a series 
of experiments examining the role of the apoptosis inhibitor BCL-2. Accordingly, 
treatment with the BCL-2 inhibitor Navitoclax partially recovered the translocation of 
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Parkin to the mitochondria, suggesting survivin acts in this process through a 
collaboration with BCL-2.  
Finally, as none of these changes occurred in normal fibroblasts in which survivin is 
not mitochondrial, and in fact forcing survivin into the mitochondria of these cells 
decreases metabolism, we conclude that the effects are exclusive to cancer cells and 
can be attributed solely to the mitochondrial pool of survivin. The targeting of 
mitochondrial survivin and the metabolic alterations it provides cancerous cells, could 
therefore offer a distinct opportunity to develop novel therapeutic treatments with 
reduced off target effects in non-cancerous cell lines.  
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Materials and Methods. 
All reagents were obtained from Sigma unless specified.  
Human Cell Culture.  
Human epithelial carcinoma cells (HeLa, ATCC), Osteosarcoma (U2OS), and normal 
lung fibroblasts (MRC5 :Medical Research Council Strain 5, Genome Stability Centre, 
Sussex),  were cultured in 5% CO2 at 37C with humidity in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Gibco, Invitrogen) supplemented with 4 mM L-glutamine, 10% Fetal 
Calf Serum (FCS, Thermo Scientific), 244 μM penicillin and 172 μM streptomycin. 
Derivative lines expressing GFP or survivin-GFP were maintained under the selection 
pressure of 1 mM G418 (Fisher). Experiments were carried out on cells within 30 
passages.  
DNA and siRNA Transfections. 
Cells were seeded into a relevant dish or imaging chamber in antibiotic free media, 
incubated for 12 h before transfection and left for approximately 48 h before use. DNA 
transfections were performed using Torpedo Transfection reagent (Ibidi) and 0.3 μg 
of relevant DNA construct, as per the manufacturer’s guidelines. siRNA transfections 
were performed using HiPerfect transfection reagent (Qiagen) and 75 ng of relevant 
siRNA, as per the manufacturer’s instruction.  
DNA constructs 
Construct Vector Reference 
GFP pcDNA 3.1+ (Carvalho et al., 2003) 
Survivin-GFP pcDNA3.1+ (Carvalho et al., 2003) 
MTS-survivin-GFP pcDNA3.1+ MTS of cytochrome c oxidase 
was amplified by PCR from 
U2OS cDNA with EcoR1 cut 
sites and inserted into SVN-GFP 
pcDNA3.1+ 
RFP pRFP1-N1 Clontech 
Survivin-RFP pRFP1-N1 Survivin was cut from survivin-
GFP pcDNA3.1+ using HindIII 
and inserted into pRFP-N1. 
mCherry-Parkin mCherry-C1 mCherry-Parkin was a gift from 
Seamus J. Martin (Hollville et 
al., 2014b) 
GST pGEX4T1 Amersham. 
GST-Parkin-WT pGEX4T1 pGEX-parkin WT was a gift from 
Kalle Gehring (Addgene 
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plasmid #45969; 
http://n2t.net/addgene:45969; 
RRID:Addgene_45969) 
(Trempe et al., 2013) 
Cell counting assay.  
Cells were seeded at a density of 200 cells per 10 cm petri dish, and the number of 
cells in individual colonies after 8, 24, 48 and 72 h.  
Immunoblotting. 
Protein samples were separated according to standard procedures using 12% 
acrylamide SDS-PAGE gels, in running buffer (25 mM Tris, 192 mM glycine, 0.1% (w/v) 
SDS) and transfer onto a 0.22 μM nitrocellulose membrane (BIOTRACE, PALL life 
sciences) using transfer buffer (24 mM Tris, 195 mM glycine, 0.1% SDS, 10% 
methanol). Post-transfer membranes were blocked with 5% non-fat milk (Marvel, in 
PBS +0.1% Tween 20 (PBST)) then incubated with appropriate primary antibody 
overnight at 4°C, washed three times with PBST then incubated in the appropriate 
horseradish peroxidase conjugated secondary antibody (see 3.5) in 5% non-fat milk. 
EZ-ECL chemiluminescence detection reagent was then added (Geneflow) and 
membrane exposed to detection film (Roche). 
Immunoblots were quantified using Fiji software. Band intensity peaks were measured 
and combined into sample groups for each condition. Within each pool, intensity 
values for each protein were expressed as a percentage of the loading control average 
and then as a percentage of the control protein average. The final expression value 
was presented as a decimal and transformed as a function of a base 2 logarithm (log2).  
Mitochondrial DNA lesion assay. 
2 x 106 cells were washed with PBS and harvested by scraping. Genomic DNA was 
extracted using the GeneJET genomic DNA purification Kit (Thermo Scientific #K0721) 
according to the manufacturer’s instructions. 
To determine mitochondrial DNA integrity, a PCR reaction was performed on gDNA 
samples using 6 ng of template gDNA, 250 μM dNTPs, 500 nM of either a short read 
(tRNA(LEU)) or a long read (LR-mtDNA) primer mix, 0.02U/μl Q5 DNA polymerase and 
1X Q5 reaction buffer. Long read PCR was aided by the addition of 10 ng/μl BSA. PCR 
products were then run on a 0.8% agarose gel and quantified using Fiji software as 
described for immunoblots.  
RNA extraction. 
7 x106 cells were harvested by scraping into 0.2 ml of media, 1 ml TRI-reagent was 
added, and the samples incubated (5 minutes at RT).  200 μl 1-Bromo-3-
chloropropane (BCP; 11.76% (v/v) in TRI reagent and residual DMEM) was then added 
and the sample incubated for a further 3 minutes at RT before centrifugation (10,000 
x g, Labnet, Prism R). The upper (colourless) layer was removed and incubated 
overnight at -20OC in acidified isopropanol solution (256 mM sodium acetate pH 4 and 
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36% isopropanol (v/v)). Samples were centrifuged at 17,000 x g for 15 minutes at 4OC 
and pellets washed in 70% ethanol. Samples were DNase treated with RNAse free 
DNase-I (Qiagen) according to the manufacturer’s instructions. RNA was isolated by 
phenol-chloroform-isoamyl-alchohol (50% phenol-chloroform-isoamy alchohol (v/v) 
125:24:1 in dH2O. Samples were vigorously shaken and incubated for 3 minutes at RT 
before centrifugation. The upper aqueous phase was transferred to a fresh tube and 
incubated overnight at -20 OC in acidified ethanol solution (323mM sodium acetate pH 
5.2 and 65% ethanol (v/v)). Precipitated samples were washed in 70% ethanol, pellets 
dried, dissolved in dH2O and RNA concentration determined by spectrophotometry 
(Nanodrop 2000, Thermo Scientific).  
Comparative qPCR. 
qPCR was performed using iTaqTM Universal SYBR® Green Supermix (BIORAD) as per 
the manufacturer’s instructions on a qPCR thermocycler (7500 fast real-time qPCR, 
Applied Biosciences). gDNA samples were analysed at a final concentration of 200 
pg/μl with 500 nM primers. Data sets were analysed, and reference genes verified 
using the Pfaffl method and REST software (QIAGEN). 
Subcellular fractionation  
Cells grown to 80-90% confluence in 15 cm2 petri dishes were washed and scraped 
into PBS and pelleted at 300 g for 3 minutes, before re-suspension in 2ml 
homogenisation buffer (200 mM Mannitol, 70 mM Sucrose, 1 mM EGTA, 10 mM 
HEPES, pH 7.5) supplemented with protease and kinase inhibitors. Lysates were 
prepared in a glass homogeniser (Teflon), a sample taken as whole cell extract, before 
spinning at 1000 g, 4C for 5 minutes. Supernatants were transferred to a fresh tube 
(mitochondrial/cytoplasmic fraction) and centrifuged at 10,000 g, 4C for 15 minutes 
to pellet mitochondria before re-suspension in homogenisation buffer. Protein 
concentration was then measured by Bradford assay and samples were boiled in SDS 
sample buffer, and 20 g protein loaded onto an SDS-page gel for analysis.  
Resazurin assays. 
Mitochondrial metabolism assays were performed using 20 μg of isolated 
mitochondria were re-suspended in Locke’s buffer (154 mM NaCl, 5.6 mM KCl (BDH), 
2.3 mM CaCl2 (Fischer), 1 mM MgCl2, 3.6 mM NaHCO3, 5 mM Glucose and 5 mM HEPES 
pH 7.5 (BDH) and plated into 1 well of a black 96 well plate (CLS3904). 40 μM resazurin 
was then added to each sample to make a final concentration of 20 μM and plates 
were then incubated at 37oC with 5% CO2. Absorbance was then read at 595nm every 
30 minutes for 4 h and compared to that of 20 μM resazurin blank controls (FluoStar 
Galaxy).  
Cell death curves were performed on 50,000 HeLa cells expressing GFP, pre-treated 
with and without 1 μM of the BCL-2 inhibitor Navitoclax for 16h. Cells were treated 
with 0, 0.02, 0.08, 0.32, 1.28 or 2.56 J of UV, left for 24 h, 20 μM of resazurin added 
and plates incubated at 37oC with 5% CO2 for 1h. Absorbance was read at 595nm and 
compared to 20 μM resazurin control.  
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Glucose-Glo and Lactate-Glo assay. 
10,000 HeLa cells were plated per well of a 96 well plate in 100 μl DMEM (Gibco 
11054001) containing 5.6 mM glucose, 2 mM glutamine and supplemented with 10% 
FCS. Media only wells acted as controls.  At 8, 24, 48 and 72 h post plating, 2.5 μl of 
media was removed from each sample, diluted in 97.5 μl of PBS and frozen until 
needed. On day of assay, samples thawed and were diluted a further 2.5 x, and 50 μl 
of diluted media added to a white 96 well plate (CLS3610) before the addition of 50 μl 
of Lactate/Glucose detection reagent (Promega). Plates were incubated for 1 h at RT 
and luminescence recorded (Glowmax Luminometer, Promega) and then compared 
to Glucose/Lactate standards to determine relevant concentrations. 
Live Cell Fluorescence imaging. 
To visualise active mitochondria, cells were grown overnight in 8-chambered micro-
slides (Ibidi). Cells were stained to visualise mitochondria using either 500 nM 
MitoTracker Red CMXRos, MitoTracker Deep Red FM or 200nM MitoTracker Green 
FM (Invitrogen), and Nucblue to visualise DNA (Thermo Fischer Scientific) in phenol-
red free CO2 independent media (DMEM, Invitrogen) supplemented with 2 mM L-
glutamine and 10% Fetal Calf Serum, for 15 minutes at 37C.  
Mitochondrial membrane potential assay.  
HeLa or MRC5 cells were seeded into Ibidi 8-chambered chambers approximately 24 
h before imaging and once adherent, were incubated in DMEM without phenol red 
(D1145) supplemented with 4 mM L-glutamine and 25 mM HEPES. 15 minutes before 
imaging, cells were stained with 1 drop of Nucblue (Life Technologies), 100 nM 
MitoTracker Green FM and 100 nM MitoTracker Deep Red FM or 200 µM 
tetramethylrhodamine ethyl ester perchlorate (TMRE, AAT Bioquest). Immediately 
before imaging, stains were washed off by replacing media with phenol red free CO2 
–independent complete DMEM.  
Image acquisition and processing.  
Imaging was performed using an inverted (DMRIB Olympus, Delta Vision Elite) 
microscope with a 60x (NA1.4, oil) objective. Single plane images were acquired, de-
convolved using inbuilt software on the Delta-vision and saved as TIFF files. Image 
pixel intensity was quantified in Fiji using a fully automated macro, which was 
programmed first to threshold each channel to a set scale defined by the user, and 
then measure the average signal intensity of each channel. Co-localisation analysis 
was performed using a similar macro that after thresholding images, was then 
programmed to analyse the percentages of pixels that spatially co-localised with 
similar intensity between the two channels. Datasets were then analysed in the 
GraphPad Prism software.  
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Figure Legends. 
 
Figure 1. Analysis of mitochondrial proteins in cancer and normal cells. (A) 
Immunoblot of the mitochondria enriched fractions (Mito) from GFP and survivin-GFP 
(SVN-GFP) overexpressing MRC5, HeLa and U2OS cells.  Whole cell extracts (WCE) are 
included in the lower panel to indicate equality in expression of each ectopic protein. 
VDAC is a mitochondrial (OMM) marker; Histone 3 indicates any nuclear 
contamination, and tubulin serves both an indicator of cytoplasmic contamination 
(Mito) and a loading control (WCE).  (B-F) Immunoblot analysis of mitochondrial 
protein expression in WCEs from HeLa sublines indicated. Compared to GFP controls 
SVN-GFP expressing cells had increased VDAC, OPA1 and MFN-2 expression and 
decreased FIS1 expression. (C) Semi-quantitative analysis of (B). Pixel intensity was 
normalised to tubulin and compared to the GFP control. A two-way ANOVA was used 
to test significance, p<0.05 (*), p<0.01 (**), p<0.001 (***), p<0.0001(****). (D) Semi-
quantitative analysis of immunoblot in (B) normalised to VDAC, statistically analysed 
using a two-way ANOVA test, p<0.0001(****). Changes in FIS1 remained significant. 
(E) Experiment described in (A) carried out in MRC5 cells.  (F) Semi-quantitative 
analysis of immunoblot in (E) normalised to tubulin. Pixel intensity quantified as 
described above (B). Two-way ANOVA shows no statistical differences in protein 
expression caused by SVN-GFP expression. All error bars indicate +/- SEM, N=3 
(triplicate). (G) qPCR analysis of mRNA to the proteins analysed in B-F expression in 
HeLa cells over-expressing GFP or SVN-GFP. VDAC mRNA remains constant, DRP1 and 
FIS1 expression are significantly increased and decreased respectively. (H) WCE’s from 
HeLa or (J) MRC5 cells over-expressing GFP or SVN-GFP and analysed by 
immunoblotting. Membranes were probed for PGC1α as a mitochondrial biogenesis 
marker, GFP to check cell line expression and tubulin as a loading control, N=3 (with 
internal triplicates). (I) and (K) Semi-quantification of immunoblots in (H) and (J) 
respectively, presented as fold change (Log2 scale) compared to the GFP control 
(TWO-way ANOVA P -value **** p<0.0001). SVN-GFP expression in HeLa cells reduces 
the expression of PGC1α but causes no alterations in MRC5 cells. 
 
Figure 2. mtDNA copy number increases but its quality decreases in HeLa cells 
expressing survivin-GFP. mtDNA copy number was determined by quantitative PCR 
on genomic DNA extracted from (A) HeLa and (B) MRC5 cells expressing GFP or SVN-
GFP. The mitochondrial encoded tRNA(LEU) gene was quantified and compared to two 
stably expressed nuclear reference genes, tubulin (TUBB) and actin (ACTB) or GAPDH. 
tRNA(LEU) was increased and decreased in SVN-GFP expressing HeLas and MRC5 cells 
respectively (p<0.0001). (C, E, G and I) Long read (LR: 9 kb) and short read (SR: 150 bp) 
PCR products derived from genomic DNA extracted from (C) HeLa cells and (G) MRC5 
cells expressing GFP or SVN-GFP, or survivin knockdown with siRNA (SVN siRNA) (E) 
and (I). LR fragments were reduced in survivin-GFP HeLas (p<0.0001) but increased 
after SVN siRNA (p=0.0008). In comparison, in MRC5 cells the 9 kb product increased 
(p<0.0001), and no change was observed after survivin depletion. (D, F, H and J) Semi-
quantitative analysis using Image J and Prism software of the 9 kb band intensity 
normalised to the 150 bp product. Statistical significance was determined using a two-
way ANOVA test, p<0.001 = ****, points show mean +/- SEM N=3 (triplicate).  
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Figure 3. Analysis of mitochondrial respiration, response to oligomycin and lactate 
production. Mitochondria were isolated from (A) HeLa, (C) U2OS or (E) MRC5 cells 
expressing GFP or SVN-GFP and plated in resazurin medium with or without 
oligomycin and metabolism assessed by absorbance, measured in relative 
fluorescence units (RFU) every 30 minutes for 4 h. Using non-linear regression analysis 
there was no line of best fit matching any pair of data sets in (A) and (C) analysis (P- 
value <0.0001), but a single curve fitted all datasets for (E); GFP, SVN-GFP, GFP + 
oligomycin and SVN-GFP + oligomycin (p values 0.9808 and 0.4123 respectively). 
Mean +/- SEM, N=3 is plotted (internally in triplicate). (B) and (D) Mitochondria from 
HeLa and U2OS display a greater fold change in resorufin fluorescence with oligomycin 
treatment compared to SVN-GFP mitochondria. Non-linear regression analysis shows 
no curve fits both HeLa/U2OS GFP and SVN-GFP oligomycin treatment data points (p 
value <0.0001). (F) Mitochondria isolated from MRC5 cells expressing GFP, SVN-GFP 
or MTS-SVN-GFP and analysed as mentioned previously. Non-linear regression 
analysis demonstrates that MTS-SVN-GFP expression reduces resorufin fluorescence 
in comparison to GFP or SVN-GFP (P-value <0.0001), Mean +/- SEM, N=3 (internally in 
triplicate). (G) Glucose consumption of 10,000 cells was measured over 72 h using a 
glucose-Glo assay. Two-way ANOVA test at 24h was used to determine significance (P- 
0.0026). Regression analysis to analyse difference in rate of change, F test proves 
significant difference (p value - 0.0176). (H) Lactate production was measured as for 
(G) using a lactate-Glo assay. Two-way ANOVA test at 24h was used to determine 
significance (P value - 0.0005). Regression analysis and F-test proves significant 
differences (p value - 0.0029). Dotted line shows glucose or lactate concentration at 
0h. Mean +/- SEM is presented, N=2 (internally in triplicate). (I) GFP and SVN-GFP 
expressing HeLa cells grow at the same rate. 200 HeLa cells were seeded and the 
number of cells per colony counted over 72 h. Mean +/- SEM is presented, N=3. 
  
Figure 4. Effect of chloroquine (CQ) treatment on mitochondrial respiration. 
Mitochondria isolated from (A and B) HeLa and (C and D) U2OS cells expressing GFP 
or SVN-GFP were plated with the addition of resazurin +/- 50 μM or 150 μM CQ and 
fluorescence absorption measured read every 30 minutes for 4 h. Non-linear 
regression shows no line fits any pair of data sets in control GFP expressing HeLa or 
U2OS mitochondria, whereas a statistical increase is seen in response to each CQ 
treatment in HeLa and U2OS cells expressing SVN-GFP, mirrored in fold change bar 
chart analysis. (E and F) Mitochondria isolated from MRC5 cells expressing GFP or SVN-
GFP display the same fold change in resorufin fluorescence post-CQ treatment. Non-
linear regression analysis shows line fits both MRC5 GFP and SVN-GFP 50 μM or 150 
μM CQ. All points indicate mean +/- SEM, N=3 (triplicate). No statistical significance is 
observed in the fold change between GFP and SVN-GFP 50 μM or 150 μM CQ 
treatments.  
Figure 5. Survivin depletion increases mitochondrial fragmentation and decreases 
mitochondrial membrane potential in cancer cells. (A and B) HeLa cells expressing 
GFP or SVN-GFP were stained with 250 nM MitoTracker Red FM and imaged live: 3 
mitochondrial phenotypes were observed; normal, intermediate or fragmented. Chi-
squared test indicated a similar mitochondrial distribution in both lines regardless of 
survivin status, N=3, DF=2. Full galleries are shown in supplementary Figures S2 and 
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S3. (C and D) Survivin overexpression does not alter mitochondrial membrane 
potential in HeLa cells but does increase mitochondrial pixel area. HeLa cells 
transiently expressing RFP or SVN-RFP were stained with MitoTracker Green (MTG) or 
MitoTracker Far Red (MTFR) and imaged live. Images were thresholded using Fiji 
software, mean pixel intensity and area was quantified and MTFR signal normalised 
to MTG. (TWO-way ANOVA, P-value ****p<0.0001). (E and F) HeLa cells were treated 
with control or survivin-specific siRNA, stained with MTG. Four mitochondrial 
phenotypes were observed; normal, fragmented, fragmented sparse and swollen. 
SVN-siRNA increased mitochondrial fragmentation (Chi-squared test, N = 3, DF=3). (G) 
Experiment described in (F) but HeLa cells were stained with MTG and TMRE.  One-
Way ANOVA indicated a statistically significant reduction in TMRE signal compared 
after SVN-siRNA, after normalisation to MTG. (H and I) MRC5 cells were treated and 
imaged as described in (F and G): neither the mitochondrial network nor its membrane 
potential was unaffected by survivin-depletion (Chi-squared test, N = 3, DF=3).  
Figure 6. Survivin does not interfere with mitophagic stages preceding Parkin 
mitochondrial translocation. (A and B) HeLa cells were treated with 10 μM FCCP for 
6 h, stained with 250 nM MitoTracker Red and imaged live. Mitochondrial distribution 
was scored as normal, fragmented, or intermediate, and no significant difference 
between cells expressing GFP or SVN-GFP was seen (Chi-squared test, N=3, DF=2). (C) 
HeLa cells transiently transfected with cDNA for RFP or SVN-RFP were treated as in (A) 
and mitochondrial membrane potential measured using MitoTracker far red, and 
expressed as a ratio to MTG. SVN-GFP expression did not alter MitoTracker Deep Red 
signal, indicating no alterations to mitochondrial membrane potential. (D, F and H) 
HeLa, U2OS and MRC5 cells were treated with 10 μM FCCP for 6, 12 and 24 hrs, WCEs 
prepared and analysed by immunoblotting. Membranes were probed for expression 
of the kinase PINK1, GFP to confirm cell line expression and tubulin used as a loading 
control N=3 (with internal triplicates). SVN-GFP expression does not alter PINK1 
stabilisation post mitophagy stimulation. (E, G and I) Semi-quantification of 
immunoblots in (D, F and H) respectively, presented as fold change (Log2 scale) 
compared to the GFP control time 0. Error bars represent +/- SEM N=3 DF=32 (with 
internal triplicates). No statistical alterations are observed (TWO-way ANOVA). (J) 
GST-pull down assay of purified GST-Parkin and GST alone using WCE made from HeLa 
GFP or SVN-GFP cells. Samples were analysed by immunoblotting, and membranes 
probed for GST to confirm pulldown, GFP to check expression in WCE’s, and PINK1 to 
assess success of pulldown. Tubulin was used as a loading control. SVN-GFP does not 
prevent the interaction of GST-Parkin with PINK1. N=3. 
Figure 7. Survivin prevents mitochondrial recruitment of mCherry-Parkin. (A) HeLa or 
(C) MRC5 cells were treated with 10 μM FCCP post-transfection with cDNA encoding 
mCherry-Parkin and stained with NucBlue to visualise nuclei. Representative images, 
thresholded using Fiji software, scale bars 15 μm. (B and C) Cells were counted for 
mitochondrial or cytoplasmic localisation of mCherry-Parkin, and a Chi-squared test 
performed to analyse differences in phenotypes. (B) In HeLa cells, Parkin relocates to 
the mitochondria in GFP cells treated with FCCP but remains cytoplasmic in SVN-GFP 
cells. (P-value ****<0.0001, N = 3). (C) No alterations were observed in mCherry-
Parkin translocation in MRC5 cells (P-value 0.6748 and 0.4112, N=3).  
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Figure 8. Mitochondrial co-localisation with lysosomes is reduced in survivin-RFP 
expressing HeLa cells. (A) HeLa cells were treated with 10 μM FCCP post-transfection 
with cDNA encoding RFP or survivin-RFP and stained with 75nM LysoTracker Blue to 
visualise lysosomes and 250nM MitoTracker Green for mitochondria. Representative 
images, thresholded using Fiji Software, scale bars 15μm. Expanded sections to show 
co-localisation of mitochondria and lysosomes. (B and C) Pixel intensity profile plots 
over a line draw through a section of RFP (B) and survivin-RFP (C) cells treated with 
FCCP. RFP cells show a co-localisation of LysoTracker Blue and MitoTracker Green 
peaks. (D) Fiji co-localisation analysis of MitoTracker Green and LysoTracker Blue 
pixels, shown as percentage co-localisation. ONE-way ANOVA analysis shows 
significant increase in co-localisation after FCCP treatment of RFP cells, but no 
alteration to survivin-RFP cells (P-value ****<0.0001, N=3). Error bars mean +/- SEM.  
Supplementary Data. 
Table 1.  qPCR primers, primer sequences for nuclear reference genes and 
mitochondrial genes of interest. F: forward; R: reverse.  
Figure S1. Survivin up-regulation increases mitomass but does not by altered 
mitochondrial biogenesis. (A) Hela, or (B) MRC5 cells were treated with mock siRNA 
or survivin siRNA, WCEs prepared and analysed by immunoblotting. Membranes were 
probed for expression of survivin, the mitochondrial proteins, VDAC, MFN1, FIS1, 
OPA1, and DRP1, and tubulin used as a loading control N=2 (with internal triplicates). 
(C) and (D) Semi-quantification of immunoblots in (A) and (B) respectively, presented 
as fold change (Log2 scale) compared to the GFP control. (TWO-way ANOVA, * p<0.05, 
** p<0.01, **** p<0.0001). Error bars represent +/- SEM N=2 (with internal 
triplicates). Survivin depletion reduces the expression of VDAC and MFN1.  
Figure S2.  Each MRC5 data set shown in Figure 3E presented individually for clarity. 
Figure S3.  Mitochondrial fragmentation is unaffected by survivin-GFP expression. 
Full figure to accompany Figure 5A. Scale bars 10 μm. 
Figure S4. Mitochondrial polarisation (TMRE) and distribution (MitoTracker green) 
after survivin siRNA. (A) HeLa and (B) MRC5 cells. Full figure accompanying Figure 5E-
I. Scale bars 10 μm. 
Figure S5. (A) mCherry-Parkin mitochondrial recruitment in MRC5 cells. Full figure 
accompanying Figure 7C. Scale bars 10 and 15 μm respectively. (B) Inhibition of Bcl-2 
increases mitochondrial translocation of Parkin in survivin-GFP expressing HeLa 
cells. HeLa cells expressing GFP or survivin-GFP were treated with 10 μM FCCP and 1 
μM Navitoclax post-transfection with cDNA encoding mCherry-Parkin. Cells were 
counted for mitochondrial or cytoplasmic localisation of mCherry-Parkin, and a Chi-
squared test performed to analyse differences in phenotypes. Images accompany 
Figure 10E.  
Figure S6. Full figure accompanying Figure 8A. Scale bars 15 μm. 
Figure S7. Inhibition of BCL-2 increases mitochondrial translocation of Parkin in 
survivin-GFP expressing HeLa cells. (A) HeLa cells expressing GFP or SVN-GFP were 
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treated with 10 μM FCCP and 1 μM Navitoclax post-transfection with cDNA encoding 
mCherry-Parkin. (B) Cells were counted for mitochondrial or cytoplasmic localisation 
of mCherry-Parkin, and a binomial test performed to test for differences to expected 
verus observed phenotypes. BCL-2 inhibition in survivin up-regulated HeLa cells 
caused increased mCherry-Parkin mitochondrial recruitment post FCCP treatment 
(****p=<0.0001). N=3, error bars represent mean +/- SEM. (C) Resazurin assay 
performed on 50,000 HeLa cells expressing GFP treated +/- 1 μM Navitoclax and 
increasing concentrations of UVC. Cells were left for 24 h post UV treatment, 20 μM 
resazurin added and absorbance read to determine cell survival. N=1 (with internal 
triplicates), error bars mean +/- SEM. 
Figure S8. Working model: Survivin inhibits Parkin-mediated mitophagy. Healthy 
mitochondria have polarized membranes and respire by OXPHOS. On encountering 
stress their mtDNA is damaged and their health compromised. Cells deal with this 
damage by fragmenting their mitochondria asymmetrically to generate two 
derivatives, one healthy mitochondrion and one that contains the defective 
components, which is then targeted for removal from the cell by a specialized form of 
autophagy, called mitophagy. Fragmentation, also called “fission” involves two 
proteins, FIS1 and DRP1, and occurs simultaneously with the depolarization of the 
OMM of the defective mitochondrion. Subsequently, the mitophagy specific E3-
ubiquitin ligase, Parkin, phosphorylated by PINK, is recruited to the OMM. In the 
absence of survivin the OMM proteins, VDAC and MFN1 get polyubiquitinated, which 
signals to adaptor proteins, such as p62, to build a pre-autophagosome around the 
defective organelle. Extension of the pre-autophagosomal membrane, which is 
facilitated by LC3II, then enables the total engulfment of the defective mitochondria. 
Finally, the autophagosome fuses with a lysosome thus completing the clearance of 
defunct mitochondria from the cell. The data herein presented, suggest that survivin 
blocks mitophagy by preventing recruitment of Parkin to the OMM. Thus, we propose 
that by inhibiting mitophagy, survivin causes an accumulation of defunct 
mitochondria, which causes cancer cells to switch their respiratory dependency from 
OXPHOS to glycolysis, aka the “Warburg Effect”.  
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Figure 8
Townley and Wheatley, 2020
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Gene F/R Sequence
Nuclear
Reference gene
ACTB
F GCAGAAAACAAGATGAGATTGGC
R TGTGAACTTTGGGGGATGCT
TUBB
F GTCCTGGATGTGGTACGGAA
R TTGCTGATAAGGAGAGTGCCC
GAPDH
F CAACAGCCTCAAGATCATCAGC
R TGGCATGGACTGTGGTCATGAG
Nuclear 
encoded gene 
for 
mitochondrial
protein
(Figure 1G)
VDAC1 F GCAAAATCCCGAGTGACCCA
R CTTTAGCCGAGAAGCAGGCG
DNML1
F AGAAAATGGGGTGGAAGCAGA
R AGGCACCTTGGTCATTCCTG
FIS1
F GGAACAGCGGGATTACGTCT
R TGCCCACGAGTCCATCTTTC
OPA1
F CGACCCCAATTAAGGACATCC
R TTCCCACACAATGTCAGGCA
MFN1
F TTACCGAGGAGGTGGCAAAC
R GGTCTGAAGCACTAAGGCGT
MFN2
F CAGGACTGGTGGAGTCAACA
R AGAGCAGGGACATTGCGTTT
Mitochondrial
Reference gene 
(Figure 3)
tRNA-Leu
(UUR)
(Rooney et al.
2015)
F
CACCCAAGAACAGGGTTTGT
R
TGGCCATGGGTATGTTGTTA
Mitochondrial
gene of interest
(Figure 3) 
LR-mtDNA
(Furda et al.
2014)
F TTTCATCATGCGGAGATGTTGGATG
G
R
TCTAAGCCTCCTTATTCGAGCCGA
Table 1: qPCR primers, primer sequences for nuclear reference genes and genes of interest. 
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